Novo Nordisk manufactures and markets pharmaceutical products and services and was created in 1989 through a merger of two Danish companies dating back to the 1920s. It produces, in particular, diabetes care equipment and medications. Novo Nordisk is also involved with haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodiesCompany headquarters are in Denmark, with production facilities in seven countries, and affiliates or offices in 76 countries. It employed approximately 29,000 people globally as of Q4 2009, and marketed its products in 179 countries. It is the largest publicly traded company in the Nordic countries by market capitalization.Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).The company was ranked 25th among 100 best companies to work for in 2010 by Fortune. In January 2012, Novo Nordisk was named as the most sustainable company in the world by the business magazine Corporate Knights.Collaborative researchToxicogenomicsNovo Nordisk is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.